Pharmaceuticals, Biotechnology and Life Sciences
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
According to Coherent Market Insights, the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is estimated to be valued at US$ 922.2 million in 2018, and is projected to exhibit a CAGR of 4.1% over the forecast period (2018–2026).
Destiny Pharma’s XF-73 nasal gel formulation has been classified non-irritant, in the second Phase 1 study, which confirms the good safety profile.
FDA has fast tracked Destiny Pharma’s lead clinical candidate exeporfinium chloride (XF-73) for the prevention of post-surgical staphylococcal infections such…
Grupo Biotoscana has launched Basilea’s hospital antibiotic Zevtera (ceftobiprole) in Argentina, Basilea Pharmaceutica said Tuesday.
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.